Page 28 - TD-3-3

Tumor Discovery Adjuvant immunotherapy in high-risk melanoma

Table 2. Baseline population characteristics
Characteristics n = 95 (%)
Age (years)
Median (range) 67.0 (24.0 – 92.0)
Sex
Female 30 (31.6)
Male 65 (68.4)
AJCC 8 ed..ition stage
th
IIIA 7 (7.4)
IIIB 27 (28.4)
IIIC 47 (49.5)
IV 14 (14.7)
Molecular status
Mutant 27 (28.4)
Figure 1. Types of primary surgical treatment
Wildtype 53 (55.8) Abbreviations: CLND: Completion lymph node dissection;
Unknown 15 (15.8) SLNB: Sentinel lymph node biopsy; WLE: Wide local excision.
Melanoma subtype
Cutaneous 87 (91.5)
Occult primary 6 (6.3)
Acral 1 (1.1)
Unknown 1 (1.1)
Patients treated with:
Pembrolizumab 8
Nivolumab 87
Abbreviation: AJCC: American Joint Committee on Cancer.

The median duration of treatment was 8.6 months,
whereas the median follow-up was 11.4 months. Around Figure 2. Reasons for stopping treatment
one-third of patients (n = 30; 31.6%) were still receiving
immunotherapy at the end of the data collection phase,
while 65 patients (68.4%) had already stopped treatment.
3.3. Efficacy
Figure 3 displays OS at 24 months, in patients with local
disease recurrence and distant recurrence (hazard ratio
[HR]: 0.75; 95% CI: 0.318 – 1.764; P > 0.05).

The 24-month OS rate was 95% (Figure 4), with
a median OS time not yet reached. In our cohort,
4 patients (3.8%) died, with three deaths attributed
to melanoma. The RFS and DRFS rates were 73%.
Overall, the median time to recurrence was 3.3 months.
Specifically, distant recurrence occurred at a median Figure 3. 24 months of overall survival in local and distant disease
of 3.5 months, while melanoma local recurrence had a recurrence groups
median of 2.9 months.
experienced both local and distant recurrence. After
Recurrence occurred in 19 patients (20%). Among these recurrence, 8 patients (8.4%) were treated with systemic
cases, 7 patients (7.3%) had local recurrence, 10 patients therapy, 6 patients (6.3%) had both local and systemic
(10.5%) had distant recurrence, and 2 patients (2.1%) therapy, 4 patients (4.2%) had only local therapy, and only

Volume 3 Issue 3 (2024) 4 doi: 10.36922/td.3143